Special Issue

Multi-Faceted Epigenetic Dysregulation in Acute Myeloid Leukemia

Message from the Guest Editors

AML is a complex heterogenous disease characterized by the presence of highly proliferative myeloid progenitor cells with reduced capacity to differentiate. Recent advanced understanding combining knowledge about recurring genetic mutations and epigenetic alterations suggests that AML is an epigenetic disease, mainly because the disease is driven by driving/recurring mutations in epigenetic modulators, DNA/chromatin modifiers, RNA splicing, 3D chromosomal interactions, and chromatin remodeling complexes SWI/SNF and NPM1. Many of these regulatory processes consist of multiple enzymes and are probably interconnected. Moreover, the role of IDR (intrinsically disordered region) in oncoproteins such as NUP98-HOXA9 or UTX to form liquid condensate that controls transcription and genome architecture has provided new insights for epigenetic understanding in AML.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: chromatin regulation, nuclear topology and 3D chromatin architecture, liquid condensates and phase separation, epi-mechanisms, RNA modifications, epi-metabolism.

Guest Editors

Dr. Shuchi Agrawal-Singh

Wellcome Trust—Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, UK

Dr. Stefanie Göllner

Department of Medicine V-Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

Deadline for manuscript submissions

closed (23 August 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/97974

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

